Skip to content
ES
MARKETS / NYSE / CCEL
NYSE · SERVICES-MISC HEALTH & ALLIED SERVICES, NEC · SMALL CAP

Cryo Cell International Inc. CCEL

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$31.6M
▼ 1.3% YoY
$-2.4M
▼ 704.2% YoY
$5.2M
▲ 45.5% YoY
In brief

What this company does

The Company, in combination with its global affiliates, currently stores over 250,000 cord blood and cord tissue specimens worldwide for the exclusive benefit of newborn babies and possibly other members of their families. The Company's U.S.-based business operations, including the processing and storage of specimens, are handled from its headquarters facility in Oldsmar, Florida. At November 30, 2025, the Company had 72 full-time employees and 4 part-time employees on the staff of the Company. None of our employees are members of any labor union, and we are not a party to any collective bargaining agreement.

Written from the business description in CRYO-CELL INTERNATIONAL, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth
USD 31.6M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 31.6 · Net income -2.4
20M-4M-8M201020122014201620182020202220242025
Compound annual growth
+1.3%
+0.3%
+4.1%
+3.9%
−27.7%
+0.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +0.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−8 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 1.5% · Net -7.7%
10%20%30%-10%-20%-30%201020122014201620182020202220242025
ROE
FY2022 · ROE 208.4%
100%200%201020122014201620182020202220242025
Gross margin76.6%
Operating margin1.5%
Net margin-7.7%
Return on assets-3.8%
EBITDAUSD 1.5M

Cash & shareholders
USD 3.4M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 5.2
4M8M-2M201020122014201620182020202220242025
Net buybacks $M Dividends $M
FY2025 · Dividends 3.2 · Net buybacks 0.1
4M8MDividendsNet buybacks2012201420162019202220242025
Dividends paidUSD 3.2M
Net buybacksUSD 146,401.00
Share of profit-139.0%
Consecutive raises—

USD 3.2M in dividends and USD 146,401.00 in buybacks went back to shareholders in a year without profit.

Total assetsUSD 61.7M
EquityUSD -18.6M
CashUSD 319,031.00
Gross debtUSD 8.4M
Net debtUSD 8.0M
Current ratio0.59×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B0.00.0−0.00.00.00.00.00.00.00.00.00.00.0−0.0−0.00.0
EBITDA $B0.00.0−0.00.00.00.00.00.00.00.00.00.00.0−0.00.0·
Income tax $B0.00.0−0.00.00.00.00.00.00.0−0.0−0.00.00.00.00.0−0.0
Net income $B−0.00.0−0.00.00.00.00.0−0.00.0−0.00.00.00.0−0.0−0.00.0
Free cash flow $B0.00.00.0−0.00.00.00.00.00.00.00.00.00.00.00.00.0
EPS, diluted $−0.300.05−1.140.330.250.450.27−0.110.30−0.160.830.050.00−0.56−0.180.29
Dividend / sh $·0.25·0.90············
Payout %−133503−02770···········
ROE %···208.4274.3···········
Shares out B0.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 63 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 16 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Misc Health & Allied Services, NEC
Listed onNYSE
Incorporated inDelaware
Fiscal year endsNovember 30
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image